Mass General Brigham Women's Heart Health Leader to Receive the 2026 Dr. Nanette K. Wenger Research Goes Red Award

Emily S. Lau, M.D., M.P.H., was selected for the American Heart Association’s 2026 Dr. Nanette K. Wenger Research Goes Red Award for research on cardiovascular disease and pregnancy. Her study analyzed 56,833 pregnancies among 38,996 individuals from 2001 to 2019; age-adjusted maternal cardiovascular disease prevalence rose from 1% to 7%, while pregnancy-related cardiovascular complications occurred in 17% of pregnancies after age adjustment. The findings also identified higher complication rates among non-Hispanic Black women and people entering pregnancy with cardiovascular risk factors.

Analysis

This is an awareness and recognition event, not a new clinical or commercial catalyst: the underlying study was published in 2025, and the award does not establish that screening changes improve outcomes or generate reimbursable demand. The investable mechanism, if validated, is greater routine cardiovascular risk assessment across preconception, obstetric and postpartum care. That could incrementally support care-management, diagnostics and remote-monitoring demand, but only if clinical workflows, reimbursement and follow-up capacity develop; the same expansion may add near-term costs for health systems without clear payment. The article provides no company-level revenue exposure, adoption data or evidence of a guideline change, so it does not support a directional position in healthcare equities.

Near term, the November Scientific Sessions may raise visibility but is unlikely by itself to move sector earnings. Over 1–3 months, monitor whether professional guidance, payer policies or health-system programs translate the research into protocols. Over 6–18 months, broader uptake could benefit providers and monitoring/diagnostic vendors, while creating execution burdens for obstetrics practices and systems serving populations with limited access. The study’s multi-institutional EHR design is informative but does not prove causation or that its prevalence estimates generalize to every care setting. A contrarian point: the growing burden may increase clinical urgency, but not necessarily commercial value—screening without funded referral and treatment pathways can raise costs rather than margins.

Key Decisions for Investors

• No immediate trade: treat the award announcement as low-signal for listed equities; no company identities or direct financial exposure are established by the supplied data.
• Set a 1–3 month watch item for AHA-session follow-through: look for guideline language, payer coverage, or named health-system pilots that include measurable screening, referral and reimbursement details.
• If adoption evidence emerges, assess diagnostics and remote-monitoring names only against verified reimbursement and utilization data; do not infer a sales tailwind from the award alone.
• Falsification/negative signal: no protocol or coverage changes, weak follow-up completion, or evidence that added screening is unfunded would undermine the commercial thesis; evidence of funded pathways and sustained uptake would strengthen it.